ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products & Appendix E – Management of Biologicals

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

- The eligibility table has been updated to include the booster dose for individuals 5-11 years of age.

COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) Pediatric (Orange Vial Cap)

- Doses and Schedule: The dose and schedule for the booster dose has been added.
- Booster Doses: The previous content stating that booster doses are not recommended has been revised to indicate that a booster dose is recommended at least 6 months after the primary series has been completed for individuals 5-11 years of age.

Monopox Vaccine

Smallpox and Monkeypox Vaccine (Live attenuated, non-replicating): IMVAMUNE®

- Administration: Storage and Handling has been updated as follows:
  o Content indicating that the vaccine will be shipped to health authorities at +2°C to +8°C refrigerator conditions for immediate use has been removed.
- Content has been added to indicate that the vaccine may be shipped at -80°C on dry ice and that these shipments must be handled by staff trained in management of dry ice.
- The expiry date information for vaccine stored at -25°C to -15°C has been revised to indicate that any time used for transport of the vaccine at -20°C is cumulative and needs to be subtracted from the allowable storage time at -25°C to -15°C.

Please remove page numbers: 1-4 dated August 8, 2022
Please add new page numbers: 1-4 dated August 26, 2022

The Monkeypox Vaccine Client Information Sheet has been updated to indicate that the vaccine is given as one dose, however people who are moderately to severely immunocompromised should get 2 doses, 4 weeks apart.

Appendix E – Management of Biologicals
Guidance for Receiving and Handling the Pfizer-BioNTech COVID-19 mRNA Vaccine (including dry ice procedures)
- The heading on page 3 for the Orange Vial Cap and Label Border has been revised to “(for those 5-11 years of age inclusive)”.

Please remove page number: 3 dated July 29, 2022
Please add new page number: 3 dated August 26, 2022
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong
Executive Director, Public Health, Planning and Prevention, Population and Public Health Division